Cardiol Therapeutics (CRDL) vs SIGA Technologies (SIGA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed SIGA Technologies (SIGA) over the past year, gaining 24.5% versus a loss of 61.4%. Over five years, SIGA leads with a -54.1% price change compared with -66.4% for CRDL. SIGA Technologies is the larger company by market cap ($231.7 million vs $160.4 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | SIGA |
|---|---|---|
| Share price | $1.32 | $3.23 |
| Market cap | $160.40M | $231.72M |
| 1-day change | 0.00% | -1.07% |
| YTD return | +38.36% | -46.64% |
| 1-year return | +24.53% | -61.37% |
| 5-year return | -66.41% | -54.15% |
| Forward P/E | — | 2.99 |
| EPS (TTM) | $-0.25 | $-0.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.34 | $8.55 |
| 52-week low | $0.88 | $2.83 |
| Distance from 52-week high | -43.59% | -62.28% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +533.33% | — |
| Average volume | 1.44M | 726.50K |
| Shares outstanding | 121.51M | 71.85M |
| Employees | 18 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed SIGA by 85.9 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About SIGA Technologies
SIGA stock →SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security market in the United States. The company's lead product is TPOXX, an antiviral drug for the treatment of human smallpox disease caused by variola virus.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
CRDL vs SIGA FAQ
Which is bigger, Cardiol Therapeutics or SIGA Technologies?
SIGA Technologies (SIGA) is larger, with a market capitalization of $231.72M compared with $160.40M for Cardiol Therapeutics (CRDL).
Which stock has performed better over the past year, CRDL or SIGA?
CRDL returned +24.53% over the past 12 months, compared with -61.37% for SIGA (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and SIGA Technologies in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Cardiol Therapeutics and Biotechnology: Pharmaceutical Preparations for SIGA Technologies.